GSK269962 | GSK269962A | CAS#850664-21-0 | ROCK inhibitor

MedKoo Cat#: 526665 | Name: GSK269962

Description:

WARNING: This product is for research use only, not for human or veterinary use.

GSK269962 is a selective ROCK inhibitor with IC50 values of 1.6 and 6 nM for ROCK-I and ROCK-II, respectively. GSK269962 can become an alternative worth considering in OAB treatment.

Chemical Structure

GSK269962

CAS#850664-21-0 (free base)

Theoretical Analysis

MedKoo Cat#: 526665

Name: GSK269962

CAS#: 850664-21-0 (free base)

Chemical Formula: C29H30N8O5

Exact Mass: 570.2339

Molecular Weight: 570.61

Elemental Analysis: C, 61.04; H, 5.30; N, 19.64; O, 14.02

Price and Availability

Size	Price	Availability
5mg	USD 90.00	Ready to ship
10mg	USD 150.00	Ready to ship
25mg	USD 300.00	Ready to ship
50mg	USD 500.00	Ready to ship
100mg	USD 850.00	Ready to ship
200mg	USD 1,500.00	Ready to ship
500mg	USD 2,950.00	Ready to ship
1g	USD 4,650.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

925213-80-5 (3HCl) 850664-21-0 (free base) 2095432-71-4 (HCl)

Synonym

GSK269962; GSK 269962; GSK-269962; GSK269962A; GSK 269962A; GSK-269962A; GSK269962B.

IUPAC/Chemical Name

N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[2-(4-morpholinyl)ethoxy]-benzamide

InChi Key

YOVNFNXUCOWYSG-UHFFFAOYSA-N

InChi Code

InChI=1S/C29H30N8O5/c1-2-37-24-17-25(31-18-23(24)33-28(37)26-27(30)35-42-34-26)41-22-5-3-4-20(16-22)32-29(38)19-6-8-21(9-7-19)40-15-12-36-10-13-39-14-11-36/h3-9,16-18H,2,10-15H2,1H3,(H2,30,35)(H,32,38)

SMILES Code

O=C(NC1=CC=CC(OC2=CC3=C(N=C(C4=NON=C4N)N3CC)C=N2)=C1)C5=CC=C(OCCN6CCOCC6)C=C5

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#C9R02B24

QC Data

View QC data: current batch, Lot#C9R02B24

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

GSK269962A HCl (GSK269962B, GSK269962) is a selective ROCK(Rho-associated protein kinase) inhibitor with IC50 values of 1.6 and 4 nM for ROCK1 and ROCK2, respectively.

In vitro activity:

GSK269962A has an IC50 value of 1.6 nM toward recombinant human ROCK1. GSK269962A also exhibited more than 30-fold selectivity against a panel of serine/threonine kinases. In lipopolysaccharide-stimulated monocytes, it blocked the generation of inflammatory cytokines, such as interleukin-6 and tumor necrosis factor-alpha. Reference: J Pharmacol Exp Ther. 2007 Jan;320(1):89-98. https://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=17018693

In vivo activity:

GSK269962A induced vasorelaxation in preconstricted rat aorta with an IC50 of 39 nM. Oral administration of either GSK269962A produced a profound dose-dependent reduction of systemic blood pressure in spontaneously hypertensive rats. At doses of 1, 3, and 30 mg/kg, it induced a reduction in blood pressure of approximately 10, 20, and 50 mm Hg. Reference: J Pharmacol Exp Ther. 2007 Jan;320(1):89-98. https://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=17018693

	Solvent	mg/mL	mM
Solubility
	DMSO	100.0	164.73
	Ethanol	28.0	46.12

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 570.61 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

In vitro protocol:

1. Doe C, Bentley R, Behm DJ, Lafferty R, Stavenger R, Jung D, Bamford M, Panchal T, Grygielko E, Wright LL, Smith GK, Chen Z, Webb C, Khandekar S, Yi T, Kirkpatrick R, Dul E, Jolivette L, Marino JP Jr, Willette R, Lee D, Hu E. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98. doi: 10.1124/jpet.106.110635. Epub 2006 Oct 3. PMID: 17018693. 2. Wang W, Chen M, Gao Y, Song X, Zheng H, Zhang K, Zhang B, Chen D. P2Y6 regulates cytoskeleton reorganization and cell migration of C2C12 myoblasts via ROCK pathway. J Cell Biochem. 2018 Feb;119(2):1889-1898. doi: 10.1002/jcb.26350. Epub 2017 Sep 7. PMID: 28815725.

In vivo protocol:

1. Doe C, Bentley R, Behm DJ, Lafferty R, Stavenger R, Jung D, Bamford M, Panchal T, Grygielko E, Wright LL, Smith GK, Chen Z, Webb C, Khandekar S, Yi T, Kirkpatrick R, Dul E, Jolivette L, Marino JP Jr, Willette R, Lee D, Hu E. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98. doi: 10.1124/jpet.106.110635. Epub 2006 Oct 3. PMID: 17018693. 2. Wróbel A, Rechberger T. The effect of combined treatment with a β3 AR agonist and a ROCK inhibitor on detrusor overactivity. Neurourol Urodyn. 2017 Mar;36(3):580-588. doi: 10.1002/nau.22978. Epub 2016 Feb 16. PMID: 26879338.

1: Wróbel A, Rechberger T. The Influence of Maxacalcitol, Vitamin D(3) Analog, on Detrusor Overactivity in Conscious Rats. Urology. 2016 Mar 23. pii: S0090-4295(16)00296-X. doi: 10.1016/j.urology.2016.03.008. [Epub ahead of print] PubMed PMID: 27018369. 2: Wróbel A, Rechberger T. Ovariectomy May Induce Detrusor Overactivity in Rats: the Therapeutic Role of Rho Kinase Inhibition. Urology. 2016 Mar 14. pii: S0090-4295(16)00295-8. doi: 10.1016/j.urology.2016.03.007. [Epub ahead of print] PubMed PMID: 26988893. 3: Wróbel A, Rechberger T. The effect of combined treatment with a β(3) AR agonist and a ROCK inhibitor on detrusor overactivity. Neurourol Urodyn. 2016 Feb 16. doi: 10.1002/nau.22978. [Epub ahead of print] PubMed PMID: 26879338. 4: Wróbel A, Rechberger T. The influence of Rho-kinase inhibition on acetic acid-induced detrusor overactivity. Neurourol Urodyn. 2015 Nov 6. doi: 10.1002/nau.22918. [Epub ahead of print] PubMed PMID: 26546786. 5: Hutchinson JL, Rajagopal SP, Yuan M, Norman JE. Lipopolysaccharide promotes contraction of uterine myocytes via activation of Rho/ROCK signaling pathways. FASEB J. 2014 Jan;28(1):94-105. doi: 10.1096/fj.13-237040. Epub 2013 Sep 27. PubMed PMID: 24076962.